↓ Skip to main content

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

Overview of attention for article published in Nucleic Acid Therapeutics, December 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#36 of 470)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news
2 news outlets
blogs
2 blogs
twitter
16 X users
patent
2 patents

Readers on

mendeley
347 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Published in
Nucleic Acid Therapeutics, December 2016
DOI 10.1089/nat.2016.0657
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 347 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 347 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 57 16%
Student > Bachelor 43 12%
Researcher 39 11%
Student > Master 36 10%
Other 21 6%
Other 51 15%
Unknown 100 29%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 77 22%
Agricultural and Biological Sciences 40 12%
Medicine and Dentistry 31 9%
Chemistry 21 6%
Pharmacology, Toxicology and Pharmaceutical Science 14 4%
Other 46 13%
Unknown 118 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 43. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2026.
All research outputs
#1,239,093
of 34,752,441 outputs
Outputs from Nucleic Acid Therapeutics
#36
of 470 outputs
Outputs of similar age
#18,736
of 460,905 outputs
Outputs of similar age from Nucleic Acid Therapeutics
#2
of 9 outputs
Altmetric has tracked 34,752,441 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 470 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 460,905 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.